MX389307B - Derivados de oxoisoquinolina novedosos - Google Patents

Derivados de oxoisoquinolina novedosos

Info

Publication number
MX389307B
MX389307B MX2019006079A MX2019006079A MX389307B MX 389307 B MX389307 B MX 389307B MX 2019006079 A MX2019006079 A MX 2019006079A MX 2019006079 A MX2019006079 A MX 2019006079A MX 389307 B MX389307 B MX 389307B
Authority
MX
Mexico
Prior art keywords
oxoisoquinoline
derivatives
novel
sup
formula
Prior art date
Application number
MX2019006079A
Other languages
English (en)
Other versions
MX2019006079A (es
Inventor
Masaaki Sawa
Shigeki Kashimoto
Takao Kiyoi
Takayuki Irie
Tokiko ASAMI
Wataru Kawahata
Original Assignee
Carna Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carna Biosciences Inc filed Critical Carna Biosciences Inc
Publication of MX2019006079A publication Critical patent/MX2019006079A/es
Publication of MX389307B publication Critical patent/MX389307B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente invencion, un derivado de oxoisoquinolina representado por la formula (I)(ver formula) (en la formula Q y R1 son como se definen en la descripcion), o una sal farmacéuticamente aceptable del mismo, es util como un inhibidor de tirosina quinasa de Bruton para tratar el cancer, linfoma de celulas ß, leucemia linfocitica cronica, y similares.
MX2019006079A 2016-11-25 2017-11-24 Derivados de oxoisoquinolina novedosos MX389307B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016229262 2016-11-25
JP2017191488 2017-09-29
PCT/JP2017/042172 WO2018097234A1 (ja) 2016-11-25 2017-11-24 新規オキソイソキノリン誘導体

Publications (2)

Publication Number Publication Date
MX2019006079A MX2019006079A (es) 2019-11-12
MX389307B true MX389307B (es) 2025-03-20

Family

ID=62195030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006079A MX389307B (es) 2016-11-25 2017-11-24 Derivados de oxoisoquinolina novedosos

Country Status (12)

Country Link
US (1) US10793575B2 (es)
EP (1) EP3546462B1 (es)
JP (1) JP7015060B2 (es)
KR (1) KR102565546B1 (es)
CN (1) CN109963852B (es)
AU (1) AU2017364720B2 (es)
CA (1) CA3044933A1 (es)
DK (1) DK3546462T3 (es)
ES (1) ES2968023T3 (es)
FI (1) FI3546462T3 (es)
MX (1) MX389307B (es)
WO (1) WO2018097234A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3896063B1 (en) 2018-12-14 2024-01-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1)
WO2021157650A1 (ja) 2020-02-05 2021-08-12 カルナバイオサイエンス株式会社 抗がん剤組成物
US20230405006A1 (en) * 2020-11-13 2023-12-21 Carna Biosciences, Inc. Combination pharmaceutical composition and treatment method
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20250074911A1 (en) 2021-12-14 2025-03-06 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
CN116854709A (zh) * 2022-03-28 2023-10-10 药雅科技(上海)有限公司 Bruton′s酪氨酸激酶可逆抑制剂及其应用
JPWO2024134859A1 (es) 2022-12-23 2024-06-27
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
CN104211703B (zh) 2013-05-30 2018-04-03 南京勇山生物科技有限公司 一类作为布鲁顿激酶抑制剂的稠杂环化合物
CN105683178B (zh) 2013-07-26 2019-04-12 卡尔那生物科学株式会社 三嗪衍生物
US20160221991A1 (en) * 2013-09-20 2016-08-04 Carna Biosciences, Inc. Novel triazine derivative

Also Published As

Publication number Publication date
CN109963852A (zh) 2019-07-02
US10793575B2 (en) 2020-10-06
CA3044933A1 (en) 2018-05-31
JPWO2018097234A1 (ja) 2019-10-17
AU2017364720A1 (en) 2019-06-20
WO2018097234A1 (ja) 2018-05-31
US20190359616A1 (en) 2019-11-28
MX2019006079A (es) 2019-11-12
RU2019119374A (ru) 2020-12-25
EP3546462A1 (en) 2019-10-02
DK3546462T3 (da) 2024-03-04
JP7015060B2 (ja) 2022-02-02
CN109963852B (zh) 2021-12-03
EP3546462B1 (en) 2024-01-03
ES2968023T3 (es) 2024-05-06
AU2017364720B2 (en) 2021-09-23
KR20190104142A (ko) 2019-09-06
KR102565546B1 (ko) 2023-08-10
BR112019010617A2 (pt) 2019-09-17
EP3546462A4 (en) 2020-07-01
FI3546462T3 (fi) 2024-01-11
RU2019119374A3 (es) 2020-12-25

Similar Documents

Publication Publication Date Title
MX389307B (es) Derivados de oxoisoquinolina novedosos
EA202193015A1 (ru) Ингибиторы cdk
MX381994B (es) Inhibidor de janus quinasa.
MX2021003478A (es) Compuestos utiles como inhibidores de cinasa.
MX384087B (es) Piperidinas como inhibidores de menina.
MX383935B (es) Amidas heterocíclicas como inhibidores de cinasa.
PH12016501693A1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
MX390625B (es) Inhibidores selectivos de jak1.
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
MD3395820T2 (ro) Compuși antitumorali
NZ748260A (en) Substituted pyrimidine bmi-1 inhibitors
CY1121334T1 (el) Αναστολεας κινασης aurora a
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EA201990833A1 (ru) Соединение пиридина
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MX382436B (es) Derivados de quinolin-2-ona.
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX383577B (es) Derivados sustituidos de guanidina.
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
MX379576B (es) Derivados de azetidina
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF